Patients who take common drugs with hypertension must check the drug after reporting that the dose strength has been printed on some packs and then checked the drug.
A larcani diphine made by Lecosati Pharm is indicated by containing 10 mg tablets when it actually contains 20 mg.
According to a warning issued by Medicines and Healthcare Products Regulatory Agency (MHRA), the correct strength is printed on the top of the box and the blister strip.
The patient must check the placement number MD4L07 as the “Prevention Measures” in January 2028.
According to MHRA, 7,700 packs were distributed.
Those who have already prescribed the drug in this batch must call NHS 111 if they cannot immediately contact or reach GP or pharmacist.
In terms of medical experts, MHRA advises patients to check the strength of the tablet by using information about the foil of the Blister strip.
Those who are prescribed 10 mg must take half of the 20mg tablet as a temporary action until they can talk to GP or pharmacist.
Lercanidipine is a calcium channel blocker that helps prevent calcium from entering the heart and vascular muscles, which helps to relax blood vessels and reduce blood pressure.
Too much can lead to fast or irregular heartbeat, dizziness or drowsiness.
Dr. Alison Cave, the chief safety officer of MHRA, said: “Patient safety is our top priority. The patient asks you to check the patient’s medicine packaging and follow the advice.
“Medical professionals like pharmacists should also stop supplying medicines and return them to suppliers in the affected deployment.
“Please report the suspected side effects through MHRA’s yellow card system.”
